KR100895134B1 - 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 - Google Patents

가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 Download PDF

Info

Publication number
KR100895134B1
KR100895134B1 KR1020027015946A KR20027015946A KR100895134B1 KR 100895134 B1 KR100895134 B1 KR 100895134B1 KR 1020027015946 A KR1020027015946 A KR 1020027015946A KR 20027015946 A KR20027015946 A KR 20027015946A KR 100895134 B1 KR100895134 B1 KR 100895134B1
Authority
KR
South Korea
Prior art keywords
delete delete
ctla4
ctla4 mutant
molecule
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027015946A
Other languages
English (en)
Korean (ko)
Other versions
KR20030009502A (ko
Inventor
로버트 제이. 피치
죠세프 알. 나에무라
피터 에스. 린슬리
유르겐 바요라트
Original Assignee
브리스톨-마이어스스퀴브컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스스퀴브컴파니 filed Critical 브리스톨-마이어스스퀴브컴파니
Publication of KR20030009502A publication Critical patent/KR20030009502A/ko
Application granted granted Critical
Publication of KR100895134B1 publication Critical patent/KR100895134B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027015946A 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 Expired - Lifetime KR100895134B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US09/579,927 2000-05-26
US21406500P 2000-06-26 2000-06-26
US60/214,065 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077017691A Division KR100889887B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20030009502A KR20030009502A (ko) 2003-01-29
KR100895134B1 true KR100895134B1 (ko) 2009-05-04

Family

ID=26908652

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020027015946A Expired - Lifetime KR100895134B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
KR1020077017691A Expired - Lifetime KR100889887B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077017691A Expired - Lifetime KR100889887B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Country Status (41)

Country Link
EP (3) EP1248802B9 (cg-RX-API-DMAC10.html)
JP (1) JP4328525B2 (cg-RX-API-DMAC10.html)
KR (2) KR100895134B1 (cg-RX-API-DMAC10.html)
CN (2) CN1309735C (cg-RX-API-DMAC10.html)
AR (1) AR031699A1 (cg-RX-API-DMAC10.html)
AT (1) ATE271066T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001263466C1 (cg-RX-API-DMAC10.html)
BE (1) BE2011C041I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0111191B8 (cg-RX-API-DMAC10.html)
CA (1) CA2409748C (cg-RX-API-DMAC10.html)
CY (2) CY2011019I2 (cg-RX-API-DMAC10.html)
CZ (1) CZ304451B6 (cg-RX-API-DMAC10.html)
DE (2) DE60104282T2 (cg-RX-API-DMAC10.html)
DK (1) DK1248802T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP024365A (cg-RX-API-DMAC10.html)
EE (2) EE05557B1 (cg-RX-API-DMAC10.html)
EG (1) EG24459A (cg-RX-API-DMAC10.html)
ES (2) ES2571852T3 (cg-RX-API-DMAC10.html)
FR (1) FR11C0053I2 (cg-RX-API-DMAC10.html)
GE (1) GEP20053658B (cg-RX-API-DMAC10.html)
HK (1) HK1048126B (cg-RX-API-DMAC10.html)
HU (2) HU228137B1 (cg-RX-API-DMAC10.html)
IL (1) IL152315A (cg-RX-API-DMAC10.html)
LT (1) LT5133B (cg-RX-API-DMAC10.html)
LU (1) LU91902I2 (cg-RX-API-DMAC10.html)
LV (1) LV12994B (cg-RX-API-DMAC10.html)
MX (1) MXPA02011534A (cg-RX-API-DMAC10.html)
MY (1) MY136113A (cg-RX-API-DMAC10.html)
NO (2) NO330797B1 (cg-RX-API-DMAC10.html)
PE (1) PE20011338A1 (cg-RX-API-DMAC10.html)
PL (1) PL206267B1 (cg-RX-API-DMAC10.html)
PT (1) PT1248802E (cg-RX-API-DMAC10.html)
RU (1) RU2283847C2 (cg-RX-API-DMAC10.html)
SI (1) SI1248802T1 (cg-RX-API-DMAC10.html)
SK (1) SK288131B6 (cg-RX-API-DMAC10.html)
TR (1) TR200402703T4 (cg-RX-API-DMAC10.html)
TW (2) TWI314933B (cg-RX-API-DMAC10.html)
UA (1) UA87432C2 (cg-RX-API-DMAC10.html)
UY (1) UY26723A1 (cg-RX-API-DMAC10.html)
WO (1) WO2001092337A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200208944B (cg-RX-API-DMAC10.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8465741B2 (en) 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
EP2678423A1 (en) 2011-02-23 2014-01-01 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
MX355234B (es) * 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) * 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN116732106A (zh) 2017-04-20 2023-09-12 E开创生物技术股份有限公司 产生基因修改的动物的方法
EP3694870A1 (en) * 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
EP4168807A1 (en) 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
CN116601279A (zh) 2020-07-28 2023-08-15 思进股份有限公司 用于生产多肽的方法和系统
IL302830A (en) 2020-11-13 2023-07-01 Egenesis Inc Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant
US20250040546A1 (en) 2021-12-16 2025-02-06 Bristol-Myers Squibb Company Detergent for viral inactivation
EP4486778A1 (en) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033513A1 (en) * 1997-01-31 1998-08-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033513A1 (en) * 1997-01-31 1998-08-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO 199833513 A1.

Also Published As

Publication number Publication date
KR20030009502A (ko) 2003-01-29
MY136113A (en) 2008-08-29
SI1248802T1 (en) 2005-02-28
PT1248802E (pt) 2004-11-30
EP1536234A2 (en) 2005-06-01
NO2011027I2 (cg-RX-API-DMAC10.html) 2011-12-15
DE60104282T2 (de) 2005-10-13
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
EE201100050A (et) 2011-10-17
WO2001092337A2 (en) 2001-12-06
MXPA02011534A (es) 2004-08-12
CA2409748A1 (en) 2001-12-06
CY1117625T1 (el) 2017-04-26
ZA200208944B (en) 2004-02-13
EP1536234A3 (en) 2009-06-03
BRPI0111191B8 (pt) 2021-05-25
HUP0302201A3 (en) 2010-01-28
CZ20023892A3 (cs) 2003-09-17
TW200906857A (en) 2009-02-16
CN1441810A (zh) 2003-09-10
KR100889887B1 (ko) 2009-03-24
DK1248802T3 (da) 2004-11-15
LT2002114A (en) 2003-12-29
TR200402703T4 (tr) 2004-11-22
WO2001092337A3 (en) 2002-05-10
ES2225549T3 (es) 2005-03-16
ATE271066T1 (de) 2004-07-15
HK1071931A1 (en) 2005-08-05
CN1309735C (zh) 2007-04-11
EP1248802B9 (en) 2005-05-11
EP1536234B1 (en) 2016-03-16
AU6346601A (en) 2001-12-11
NO330797B1 (no) 2011-07-18
UA87432C2 (uk) 2009-07-27
ES2571852T3 (es) 2016-05-27
CN101255192A (zh) 2008-09-03
NO20025656D0 (no) 2002-11-25
NO2011027I1 (no) 2012-01-09
HK1048126A1 (en) 2003-03-21
LT5133B (lt) 2004-05-25
AR031699A1 (es) 2003-10-01
LV12994B (en) 2003-08-20
EE05557B1 (et) 2012-08-15
IL152315A0 (en) 2003-05-29
TWI319405B (en) 2010-01-11
FR11C0053I1 (cg-RX-API-DMAC10.html) 2012-01-13
PL366231A1 (en) 2005-01-24
HU228137B1 (en) 2012-12-28
FR11C0053I2 (fr) 2013-01-11
AU2001263466B2 (en) 2006-04-27
TWI314933B (en) 2009-09-21
IL152315A (en) 2010-04-15
RU2283847C2 (ru) 2006-09-20
CY2011019I1 (el) 2016-12-14
SK288131B6 (sk) 2013-10-02
CZ304451B6 (cs) 2014-05-14
PL206267B1 (pl) 2010-07-30
HUS1300012I1 (hu) 2016-08-29
JP2004511213A (ja) 2004-04-15
PE20011338A1 (es) 2002-01-13
BR0111191A (pt) 2004-07-06
EE200200659A (et) 2004-06-15
GEP20053658B (en) 2005-11-10
BE2011C041I2 (cg-RX-API-DMAC10.html) 2020-08-20
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
DE122011100063I1 (de) 2012-06-14
EP1248802B1 (en) 2004-07-14
ECSP024365A (es) 2003-03-31
CA2409748C (en) 2008-09-16
SK15702002A3 (sk) 2004-01-08
EG24459A (en) 2009-07-16
UY26723A1 (es) 2001-12-28
AU2001263466C1 (en) 2006-10-26
DE60104282D1 (de) 2004-08-19
BRPI0111191B1 (pt) 2019-12-31
EE05458B1 (et) 2011-08-15
HUP0302201A2 (hu) 2003-10-28
EP3029062A1 (en) 2016-06-08
HK1048126B (en) 2005-03-04
JP4328525B2 (ja) 2009-09-09
NO20025656L (no) 2002-11-25

Similar Documents

Publication Publication Date Title
KR100889887B1 (ko) 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
KR100864120B1 (ko) 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
US20210115107A1 (en) Methods of treatment using ctla4 molecules
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
HK1225393A1 (en) Soluble ctla4 mutant molecules and uses thereof
HK1071931B (en) Soluble ctla4 mutant molecules and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060522

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070430

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070731

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071231

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080716

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090420

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090420

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120409

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120409

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130403

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130403

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140331

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140331

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150323

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150323

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160318

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160318

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170317

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170317

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180315

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180315

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190315

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190315

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20200317

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200317

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20210324

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20210324

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term